|
WO2021011795A1
|
|
Automated cranial burr hole device and method
|
|
WO2020247654A1
|
|
Setbp1 and xpo1 inhibitors for the treatment of sickle cell disease and beta-thalassemia
|
|
WO2020167729A1
|
|
Vaccine-induced gene signatures correlating with protection against hiv and siv infection
|
|
WO2020123880A2
|
|
Genomic rearrangements associated with prostate cancer and methods of using the same
|
|
CA3110571A1
|
|
Compositions and methods for preventing and/or treating filarial disease
|
|
WO2020051293A1
|
|
Recurrence gene signature across multiple cancer types
|
|
WO2019231819A1
|
|
Methods of treating myeloproliferative disorders
|
|
WO2019226773A1
|
|
Setbp1 inhibitors for the treatment of myeloid neoplasms and solid tumors
|
|
WO2019213047A1
|
|
Detection of autoantibodies against deiminated protein epitopes associated with brain oxygen deprivation
|
|
WO2019209974A2
|
|
Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination
|
|
US2021017540A1
|
|
Immortalization of Splenic and Peripheral Blood Macrophages Using a Multi-Cistronic V-RAF/V-MYC Lentivirus
|
|
EP3731860A1
|
|
Compositions and methods for treating autoimmune disease
|
|
EP3707127A1
|
|
Compounds for inhibiting ly6k and methods of using same
|
|
WO2019018368A1
|
|
Antibacterial methods and related kits
|
|
WO2018223124A2
|
|
Predictive factors for successful wound closure
|
|
WO2018223001A1
|
|
Predictive factors for timing of wound closure
|
|
WO2018223005A1
|
|
Predictive factors for venous thromboembolism
|
|
WO2018223008A1
|
|
Predictive factors for predicting laparotomy closure
|
|
WO2018223006A1
|
|
Predictive factors for acute kidney injury
|
|
US2021108271A1
|
|
Prostate cancer gene profiles and methods of using the same
|
